North Carolina Central University
1801 Fayetteville St.
Durham, NC 27707
Pancreatic ductal adenocarcinoma (PDAC) is highly aggressive and almost always fatal. Currently, there are no biomarkers for early detection and treatment options are very limited. Although the presence of oncogenically mutated K-Ras in 90% of PDAC strongly suggests a critical role for this genetic mutation in the development of this disease, to date no anti-Ras therapies have successfully reached the clinic. Antonio T. Baines’ lab is working to identify and validate the role of novel molecular targets in the development and transformation of normal pancreatic cells into pancreatic cancer.